These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib. Dasmahapatra G; Patel H; Dent P; Fisher RI; Friedberg J; Grant S Br J Haematol; 2013 Apr; 161(1):43-56. PubMed ID: 23360303 [TBL] [Abstract][Full Text] [Related]
85. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia. Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464 [TBL] [Abstract][Full Text] [Related]
86. Hypertonicity counteracts MCL-1 and renders BCL-XL a synthetic lethal target in head and neck cancer. Heimer S; Knoll G; Neubert P; Hammer KP; Wagner S; Bauer RJ; Jantsch J; Ehrenschwender M FEBS J; 2021 Mar; 288(6):1822-1838. PubMed ID: 32710568 [TBL] [Abstract][Full Text] [Related]
87. Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms. Nguyen T; Parker R; Zhang Y; Hawkins E; Kmieciak M; Craun W; Grant S BMC Cancer; 2018 Nov; 18(1):1129. PubMed ID: 30445933 [TBL] [Abstract][Full Text] [Related]
88. Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK. Wang X; Fei Y; Liu X; Zhang T; Li W; Jia X; Liu X; Qiu L; Qian Z; Zhou S; Ren X; Zhai Q; Meng B; Li L; Zhang H Aging (Albany NY); 2021 Sep; 13(17):21102-21121. PubMed ID: 34508613 [TBL] [Abstract][Full Text] [Related]
89. Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines. Restelli V; Lupi M; Vagni M; Chilà R; Bertoni F; Damia G; Carrassa L Target Oncol; 2018 Apr; 13(2):235-245. PubMed ID: 29441438 [TBL] [Abstract][Full Text] [Related]
90. Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma. Algarín EM; Díaz-Tejedor A; Mogollón P; Hernández-García S; Corchete LA; San-Segundo L; Martín-Sánchez M; González-Méndez L; Schoumacher M; Banquet S; Kraus-Berthier L; Kloos I; Derreal A; Halilovic E; Maacke H; Gutiérrez NC; Mateos MV; Paíno T; Garayoa M; Ocio EM Haematologica; 2020 Mar; 105(3):e116-e120. PubMed ID: 31320555 [No Abstract] [Full Text] [Related]
97. Targeting MCL-1 dysregulates cell metabolism and leukemia-stroma interactions and resensitizes acute myeloid leukemia to BCL-2 inhibition. Carter BZ; Mak PY; Tao W; Warmoes M; Lorenzi PL; Mak D; Ruvolo V; Tan L; Cidado J; Drew L; Andreeff M Haematologica; 2022 Jan; 107(1):58-76. PubMed ID: 33353284 [TBL] [Abstract][Full Text] [Related]
98. AMG-176, an Mcl-1 Antagonist, Shows Preclinical Efficacy in Chronic Lymphocytic Leukemia. Yi X; Sarkar A; Kismali G; Aslan B; Ayres M; Iles LR; Keating MJ; Wierda WG; Long JP; Bertilaccio MTS; Gandhi V Clin Cancer Res; 2020 Jul; 26(14):3856-3867. PubMed ID: 31937611 [TBL] [Abstract][Full Text] [Related]
99. The novel BH3 α-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein-protein interactions with Bak. Cao X; Yap JL; Newell-Rogers MK; Peddaboina C; Jiang W; Papaconstantinou HT; Jupitor D; Rai A; Jung KY; Tubin RP; Yu W; Vanommeslaeghe K; Wilder PT; MacKerell AD; Fletcher S; Smythe RW Mol Cancer; 2013 May; 12(1):42. PubMed ID: 23680104 [TBL] [Abstract][Full Text] [Related]
100. MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-X Yasuda Y; Ozasa H; Kim YH; Yamazoe M; Ajimizu H; Yamamoto Funazo T; Nomizo T; Tsuji T; Yoshida H; Sakamori Y; Nakajima N; Menju T; Yoshizawa A; Date H; Hirai T Cell Death Dis; 2020 Mar; 11(3):177. PubMed ID: 32152266 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]